Company intelligence / Profile preview

NEX-I

Ownership: Private
Development stage: Preclinical

Overview

NEX-I is developing NXI-101, a first-in-class antibody drug targeting ONCOKINE-1, a factor produced by cancer cells that contributes to resistance to cancer immunotherapy[1].

Therapeutic areas: Oncology
Modalities: Antibody drugs
Industry: Biotech

Drug pipeline

5 assets

NXI-401

Preclinical

4 more assets in the full pipeline.

Partnerships

Xsphera Biosciences Inc.

Beyond the preview

Go deeper on NEX-I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEX-I.